Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 46 min ago
Peer-reviewedCC BY-NC-ND 4.0Translational Oncology

Integrative multi-omics analysis identifies SLCO1B3 as a prognostic marker and functional oncogenic driver in head and neck squamous cell carcinoma

  1. 1Department of Otorhinolaryngology and Head and Neck Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221000, China

Abstract

Background: Head and neck squamous cell carcinoma (HNSCC) is a leading cause of cancer mortality with limited prognostic biomarkers. Given the role of metabolic reprogramming in tumor progression, this study investigated the clinical relevance and biological function of the lipid metabolism-associated transporter SLCO1B3 in HNSCC.

Methods: We integrated bulk transcriptomic data from The Cancer Genome Atlas (TCGA) and multiple independent cohorts with single-cell RNA sequencing, high-dimensional weighted gene co-expression network analysis (hdWGCNA), spatial transcriptomics, and in vitro loss-of-function assays in SCC9 cells.

Results: SLCO1B3 was significantly upregulated in HNSCC and independently predicted poor survival across multiple cohorts. Single-cell analysis localized SLCO1B3 to an epithelial subpopulation with enhanced stemness, evidenced by elevated CytoTRACE scores and pseudotime trajectory mapping. hdWGCNA identified co-expression modules enriched in cell cycle regulation and stress responses within SLCO1B3-positive epithelial cells. Spatial transcriptomics revealed preferential colocalization of SLCO1B3-positive cells with fibroblasts and smooth muscle cells. Cell-cell communication analysis further showed distinct ligand-receptor interaction patterns mediated by SLCO1B3-positive epithelial cells. Functionally, SLCO1B3 knockdown induced G0/G1 arrest, suppressed migration and invasion, and promoted apoptosis, accompanied by altered expression of Cyclin D1, PCNA, and p21.

Conclusion: These findings establish SLCO1B3 as an independent prognostic biomarker and functional driver that sustains stemness and malignant phenotypes in HNSCC, providing a rationale for its therapeutic targeting.

Related

  1. Integrative Multi-Database Bioinformatics Characterization of FANCE in Hepatocellular Carcinoma: Prognostic, Epigenetic, Immune, and ncRNA Associations
    Yeong Chae Kim, Kyu-Shik Lee, Hye-Ran Kim +1
    Medicina (Kaunas, Lithuania)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Pan-cancer analysis identifies ANGPT4 as a potential prognostic biomarker associated with the tumor microenvironment in kidney renal clear cell carcinoma
    Pengfei Chen, Kangmei Tong, Lisheng You +3
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicineCrossref
  3. Integrative Multi-omics and machine learning analysis of sphingolipid-associated molecular stratification identifies diagnostic and prognostic signatures in idiopathic pulmonary fibrosis
    Yi Liao, Lingjing Yang, Xiaoshu Liu +1
    Orphanet Journal of Rare DiseasesPeer-reviewedCC BY 4.0Full text1 citedGeneral medicinePMC
  4. Pan-Cancer Analysis Identifies LUC7L2 as a Prognostic Biomarker and Potential Functional Regulator of Prostate Cancer Progression
    Jialin Yuan, Ping Zhan, Jun Liu +4
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Integrated single-cell and machine learning analysis identifies an autophagy- and immune-related prognostic signature in adrenocortical carcinoma
    Yuezhou Chen, Shengjie Lai, Sijian Fang +5
    Discover OncologyPeer-reviewedCC BYFull textSurgery & anaesthesiaDOAJ
BibTeX
@article{zhao2026integrative,
  title = {{Integrative multi-omics analysis identifies SLCO1B3 as a prognostic marker and functional oncogenic driver in head and neck squamous cell carcinoma}},
  author = {Xiaotong Zhao and Yongpeng Chen and Hongjiang Wang},
  journal = {Translational Oncology},
  year = {2026},
  month = oct,
  doi = {10.1016/j.tranon.2026.103088},
  url = {https://doi.org/10.1016/j.tranon.2026.103088},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Integrative multi-omics analysis identifies SLCO1B3 as a prognostic marker and functional oncogenic driver in head and neck squamous cell carcinoma
AU  - Xiaotong Zhao
AU  - Yongpeng Chen
AU  - Hongjiang Wang
PY  - 2026
DA  - 2026/10/26
JO  - Translational Oncology
DO  - 10.1016/j.tranon.2026.103088
UR  - https://doi.org/10.1016/j.tranon.2026.103088
AB  - Background: Head and neck squamous cell carcinoma (HNSCC) is a leading cause of cancer mortality with limited prognostic biomarkers. Given the role of metabolic reprogramming in tumor progression, this study investigated the clinical relevance and biological function of the lipid metabolism-associated transporter SLCO1B3 in HNSCC.  Methods: We integrated bulk transcriptomic data from The Cancer Genome Atlas (TCGA) and multiple independent cohorts with single-cell RNA sequencing, high-dimensional weighted gene co-expression network analysis (hdWGCNA), spatial transcriptomics, and in vitro loss-of-function assays in SCC9 cells.  Results: SLCO1B3 was significantly upregulated in HNSCC and independently predicted poor survival across multiple cohorts. Single-cell analysis localized SLCO1B3 to an epithelial subpopulation with enhanced stemness, evidenced by elevated CytoTRACE scores and pseudotime trajectory mapping. hdWGCNA identified co-expression modules enriched in cell cycle regulation and stress responses within SLCO1B3-positive epithelial cells. Spatial transcriptomics revealed preferential colocalization of SLCO1B3-positive cells with fibroblasts and smooth muscle cells. Cell-cell communication analysis further showed distinct ligand-receptor interaction patterns mediated by SLCO1B3-positive epithelial cells. Functionally, SLCO1B3 knockdown induced G0/G1 arrest, suppressed migration and invasion, and promoted apoptosis, accompanied by altered expression of Cyclin D1, PCNA, and p21.  Conclusion: These findings establish SLCO1B3 as an independent prognostic biomarker and functional driver that sustains stemness and malignant phenotypes in HNSCC, providing a rationale for its therapeutic targeting.
SN  - 1936-5233
ER  -